Analysis of multiple sarcoma expression datasets: Implications for classification, oncogenic pathway activation and chemotherapy resistance

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Konstantinopoulos, Panagiotis A ^a   Fountzilas, Elena ^a   Goldsmith, Jeffrey D ^a   Bhasin, Manoj ^a   Pillay, Kamana ^a   Francoeur, Nancy ^a   Libermann, Towia A ^a   Gebhardt, Mark C ^a   Spentzos, Dimitrios ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN;

ADIPOCYTE; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FIBROBLAST; FIBROSARCOMA; GENE ACTIVATION; GENE CLUSTER; GENE MAPPING; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; NERVE SHEATH TUMOR; ONCOGENE; PREDICTION; RHABDOMYOSARCOMA; SMOOTH MUSCLE; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TISSUE DIFFERENTIATION; VALIDATION STUDY; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; CLASSIFICATION; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG RESISTANCE; EXPERT SYSTEM; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; NUCLEIC ACID DATABASE; SARCOMA; SOFT TISSUE TUMOR;

BAYES THEOREM; CLUSTER ANALYSIS; DATABASES, NUCLEIC ACID; DRUG RESISTANCE, NEOPLASM; EXPERT SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; NEURAL NETWORKS (COMPUTER); OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 77956299890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009747     Document Type: Article

References (42)

1. Fletcher CD (1997) Soft tissue tumours: the impact of cytogenetics and molecular genetics. Verh Dtsch Ges Pathol 81: 318-326.
2. Nascimento AF, Raut CP (2008) Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults. J Surg Oncol 97: 330-339.
3. Goldberg BR (2007) Soft tissue sarcoma: An overview. Orthop Nurs 26: 4-11; quiz 12-13.
4. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626-632.
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
6. de Alava E (2007) Molecular pathology in sarcomas. Clin Transl Oncol 9: 130-144.
7. Lawrence W, Jr., Donegan WL, Natarajan N, Mettlin C, Beart R, et al. (1987) Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 205: 349-359.
8. Daugaard S (2004) Current soft-tissue sarcoma classifications. Eur J Cancer 40: 543-548.
9. Brenton JD, Aparicio SA, Caldas C (2001) Molecular profiling of breast cancer: portraits but not physiognomy. Breast Cancer Res 3: 77-80.
10. Hegde U, Wilson WH (2001) Gene expression profiling of lymphomas. Curr Oncol Rep 3: 243-249.
11. Liotta L, Petricoin E (2000) Molecular profiling of human cancer. Nat Rev Genet 1: 48-56.
12. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, et al. (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65: 9226-9235.
13. Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, et al. (2005) A molecular map of mesenchymal tumors. Genome Biol 6: R76.
14. Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP (2007) Subclass mapping: identifying common subtypes in independent disease data sets. PLoS ONE 2: e1195.
15. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
16. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, et al. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038.
17. Fletcher CD (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16: 213-228.
18. Nakayama R, Nemoto T, Takahashi H, Ohta T, Kawai A, et al. (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20: 749-759.
19. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, et al. (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359: 1301-1307.
20. Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23: 7332-7341.
21. Quackenbush J (2006) Microarray analysis and tumor classification.N Engl JMed 354: 2463-2472.
22. Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D'Amore PA, et al. (2005) Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65: 5881-5889.
23. Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12: 589-603.
24. Blay JY, Ray-Coquard I, Alberti L, Ranchere D (2004) Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPARgamma in liposarcomas. Cancer Treat Res 120: 151-167.
25. Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, et al. (2008) Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 68: 346-351.
26. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, et al. (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11: 6280-6290.
27. Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19: 3045-3050.
28. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355.
29. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, et al. (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7: 1-9.
30. Calin GA, Croce CM (2006) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394.
31. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
32. Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, et al. (2004) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165: 1799-1807.
33. Bibikova M, Yeakley JM, Wang-Rodriguez J, Fan JB (2008) Quantitative expression profiling of RNA from formalin-fixed, paraffin-embedded tissues using randomly assembled bead arrays. Methods Mol Biol 439: 159-177.
34. Dabney AR (2005) Classification of microarrays to nearest centroids. Bioinformatics 21: 4148-4154.
35. Dabney AR, Storey JD (2007) Optimality driven nearest centroid classification from genomic data. PLoS ONE 2: e1002.
36. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127.
37. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
38. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
39. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12: 1294-1300.
40. Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, et al. (2008) Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299: 1574-1587.
41. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advancedstage ovarian cancer. J Clin Oncol 25: 517-525.
42. Pavlidis P, Qin J, Arango V, Mann JJ, Sibille E (2004) Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res 29: 1213-1222.